期刊文献+

心房颤动对肥厚型心肌病患者长期预后的影响 被引量:12

Influence of atrial fibrillation on long-term prognosis of patients with hypertrophic cardiomyopathy
原文传递
导出
摘要 目的分析心房颤动(房颤)对肥厚型心肌病(hypertrophic cardiomyopathy,HCM)患者长期预后的影响。方法回顾性分析573例HCM患者的临床资料,记录患者病死率、HCM相关死亡因素、心功能状态、心力衰竭再住院率、脑卒中发生情况及抗凝药物应用情况,采用COX回归分析做出生存曲线,分析房颤对HCM患者长期预后的影响。结果 467患者完成随访,随访率81.5%,随访时间6个月~10a;其中123例(26.3%)有阵发性或永久性房颤;随访结束时死亡42例,其中HCM相关死亡31例;房颤患者心功能Ⅲ~Ⅳ级(55.3%)比例高于无房颤患者(21.8%)(P<0.01),脑卒中发生率(22.0%)高于无房颤患者(2.3%)(P<0.01)。结论房颤可增加HCM患者脑卒中发生概率,降低患者心功能状态,降低HCM患者长期生存率。 Objective To analyze the influence of atrial fibrillation (AF) on the long-term prognosis of the patients with hypertrophic eardiomyopathy (HCM). Methods The clinical data of 573 cases of HCM were analyzed retrospectively to record the overall mortality, HCM related death factors, cardiac function, the rate of readmission due to heart failure, stroke occurrence and the use of anticoagulation drugs. COX regression analysis was used to make survival curve to analyze the influence of atrial fibrillation on the long-term prognosis of HCM. Results A total of 467 patients were followed up (81.5%) for 0.6 to 10 (6.4±2.6) years, among which 123 patients (26.3%) suffered from paroxysmal or permanent AF. At the end of follow up survey 42 patients died, including 31 cases of HCM related death. The proportion of cardiac function of grade Ⅲ to Ⅳ level was higher in patients with AF (55. 3%) than that in patients without AF (21.8%)(P〈0.01). The incidence of stroke was higher in patients with AF (22.0%) than that in those without AF (2.3%) (P〈0.01). Conclusion Atrial fibrillation increases stroke risk, and reduces the cardiac function and the long-term survival rate in patients with HCM.
出处 《中华实用诊断与治疗杂志》 2013年第2期126-128,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 肥厚型心肌病 心房颤动 心功能 脑卒中 预后 Hypertrophic cardiomyopathy atrial fibrillation cardiac function stroke prognosis
  • 相关文献

参考文献11

二级参考文献48

  • 1孟旭,李金钟,刘岩,张海波.人工机械瓣膜置换术后口服抗凝药的抗凝治疗强度标准[J].中华心血管病杂志,2004,32(7):618-621. 被引量:58
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 3赵秀敏.房颤致脑栓塞60例临床分析[J].中国实用神经疾病杂志,2006,9(4):100-101. 被引量:26
  • 4刘辉,张彦周,郝静,邹汇菲,康瑜,毛家亮,何奔.索他洛尔治疗剂量对华法令抗凝药效的相关性研究[J].实用诊断与治疗杂志,2007,21(6):404-405. 被引量:1
  • 5中华神经科学会 中华神经外科学会.脑血管疾病分类及诊断要点[J].中华神经科杂志,1996,29(6):376-379.
  • 6Chugh S S, Blackshear J L, Shen W K, et al. Epidemiology and natural history of atrial fibrillation: clinical implications[J]. J Am Coll Cardiol,2001,37(2) :371-378.
  • 7Fuster V, Ryden L E, Cannom D S, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) : developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J]. Circulation, 2006,114 (6): e257-354.
  • 8Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery[J]. Circulation, 2004,110(11 Suppl 1): Ⅱ45-49.
  • 9Wheeldon N. Coronary heart disease and atrial fibrillation. Studies have not shown a causal relation[J]. BMJ, 1996,312 (7031):641-642.
  • 10Cameron A, Schwartz M J, Kronmal R A, et al. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry)[J]. Am J Cardiol,1988 , 61(10) : 714-717.

共引文献1441

同被引文献105

  • 1安丰双,张运,李大庆,杨兴胜,李莉,张澄,颜默磊,王燕,安贵鹏.肥厚型心肌病肌钙蛋白T基因突变的研究[J].中华医学杂志,2004,84(16):1340-1343. 被引量:5
  • 2张蔚湜.缺血性心脏病的概念及分类界定标准[J].职业与健康,2005,21(11):1698-1700. 被引量:5
  • 3刘和俊,曹克将,李诚让,戴健,马继政,雍永宏,孙伟.肥厚型心肌病样临床表现的FABRY病家系研究[J].中华心血管病杂志,2006,34(2):143-147. 被引量:6
  • 4赖雅敏,李玲,张抒扬,朱文玲,郭丽琳.Fabry病累及心脏一例[J].中华内科杂志,2006,45(6):510-510. 被引量:2
  • 5Desnick R J, Brady R, Barrangcr J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy[J]. Ann Intern Med. 2003.138(4);338- 346.
  • 6Linthorst G E, Bouwman M G, Wijburg F A, et al. Screening for Fabry disease in high-risk populations; a systematic review [J]. J MedGenet,2010,47(4);217-222.
  • 7Desnick R J. Enzyme replacement and beyond[J]. J Inherit Metadol Dis,2001,24(2) :251-265.
  • 8Keren A, Syrris P, McKenna W J. Hypertrophic cardiomyopathy~ the genetic determinants of clinical disease expression[J] Nat Clin Pract Cardiovasc Med,2008,5(3):158- 168.
  • 9Millat G, Bouvagnet P, Chevalier P, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopath[J]. Eur J Med Genet, 2010, 53 (5) ~261-267.
  • 10Colombo M G, Botto N, Vittorini S, et al. Clinical utility of genetic tests for inherited hypertrophic and dilated eardiomyopathies[J]. Cardiovasc Ultrasound, 2008,6 (6) : 62.

引证文献12

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部